SavedAdd your journal

Journals / İnfeksiyon Dergisi / 2006 / Cilt: 20 - Sayı: 3

Antiretroviral treatment

Antiretroviral tedavi

Nesrin TÜRKER
Bahar ÖRMEN
Pages
207–217
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper; the pretreatment evaluation of antiretroviral treatment, treatment goals, when to treat, benefits and risks of treatment and combination regimens for the antiretroviral naive patients are reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:There is a rapid progress in the treatment of Human Immunodeficiency Virus (HIV) type 1 infection.
📊
Key Findings & Data:There is a rapid progress in the treatment of Human Immunodeficiency Virus (HIV) type 1 infection.
💡
Conclusion & Impact:In this paper; the pretreatment evaluation of antiretroviral treatment, treatment goals, when to treat, benefits and risks of treatment and combination regimens for the antiretroviral naive patients are reviewed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

There is a rapid progress in the treatment of Human Immunodeficiency Virus (HIV) type 1 infection. In this paper; the pretreatment evaluation of antiretroviral treatment, treatment goals, when to treat, benefits and risks of treatment and combination regimens for the antiretroviral naive patients are reviewed.

Özet

nsan İmmun Yetmezlik Virusu (HIV) tip 1'in tedavisinde çok hızlı bir gelişim vardır. Bu makalede, antiretroviral tedavi öncesi hastaya yaklaşım, tedavi hedefleri, ne zaman başlanması gerektiği, risk ve yararları ve tedavi görmemiş hastadaki tedavi kombinasyonları özetlenerek sunulmuştur.

🔖

Cite This Article

TÜRKER, N., ÖRMEN, B. (2022). Antiretroviral treatment. İnfeksiyon Dergisi, Cilt: 20 - Sayı: 3, 207–217. https://ajindex.com/articles/546416

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Hanna GJ, Hırsch MS. Antiretroviral therapy for human immunodeficiency virus infection. In: Mandell GL, Douglas RG, Dolin R, eds. Principles and Practice of Infectious Diseases. Vol 1. 6th ed. New York: Churchill Livingstone, 2005: 1655-78
  2. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004; 39: 609-29
  3. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163: 2187-95
  4. Mellors JW, Rinaldo CR Jr, Gupta P, White RM.Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70
  5. Anonymous. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS), 2004
  6. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4 (+) T cells during primary HIV-1 infection. Proc NatlAcad Sci USA 1998; 95: 8869-73
  7. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-30
  8. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60
  9. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179: 717-20
  10. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13: 1873-80
  11. Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15: 735-46
  12. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficie